A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Recruiting

Phase 1

JNJ-87704916 & CetrelimabA Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Sponsor:

Johnson & Johnson Enterprise Innovation Inc.

Code:

NCT06311578

Conditions

Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

JNJ-87704916

Cetrelimab

Standard of Care PD(L)-1

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-04. This information was provided to ClinicalTrials.gov by Johnson & Johnson Enterprise Innovation Inc. on 2026-05-08.